Prolonged haematologic toxicity in CAR-T-cell therapy: A review

被引:2
|
作者
Liu, Qi [1 ,2 ]
Hu, Tonglin [1 ,2 ]
Li, Hangchao [1 ,2 ]
Shen, Yingying [1 ,2 ]
Wu, Dijiong [1 ,2 ]
Ye, Baodong [1 ,2 ]
机构
[1] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Hematol, Hangzhou 310005, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
CAR-T-cell therapy; management; mechanism; prolonged haematologic toxicity; HEMATOPOIETIC STEM-CELLS; TISAGENLECLEUCEL; ELTROMBOPAG; MULTICENTER; CHILDREN; EFFICACY; ADULTS; GAMMA;
D O I
10.1111/jcmm.17930
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chimeric antigen receptor-T-cell (CAR-T-cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune-mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR-T cells used and diseases treated as well as differences in the definition of PHT, its rate, risk factors and management vary across studies. In this review, we provide a narrative of PHT occurring in patients following CAR-T-cell therapy; evidence of PHT treatment strategies is also presented, with the aim of contributing to systematic understanding of PHT.
引用
收藏
页码:3662 / 3671
页数:10
相关论文
共 50 条
  • [1] Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy
    Kitamura, Wataru
    Asada, Noboru
    Naoi, Yusuke
    Abe, Masaya
    Fujiwara, Hideaki
    Ennishi, Daisuke
    Nishimori, Hisakazu
    Fujii, Keiko
    Fujii, Nobuharu
    Matsuoka, Ken-ichi
    Yoshino, Tadashi
    Maeda, Yoshinobu
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (02) : 294 - 307
  • [2] Dynamic imaging for CAR-T-cell therapy
    Emami-Shahri, Nia
    Papa, Sophie
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2016, 44 : 386 - 390
  • [3] Advances in CAR-T-cell therapy in T-cell malignancies
    Zheng, Rubing
    Zhu, Xiaojian
    Xiao, Yi
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [4] outlook A solid start for CAR-T-cell therapy
    Dolgin, Elie
    [J]. NATURE, 2022, 612 (7941) : S50 - S52
  • [5] Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: A review
    Peng, Xiaojuan
    Zhang, Xialin
    Zhao, Meiling
    Chang, Doudou
    Yang, Linhua
    Mei, Heng
    Zhang, Ruijuan
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (02) : 420 - 428
  • [6] Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
    Li, Hujun
    Zhao, Lina
    Sun, Zengtian
    Yao, Yue
    Li, Li
    Wang, Jiaojiao
    Hua, Tian
    Ji, Shengwei
    Wang, Shiyuan
    Cheng, Hai
    Shi, Ming
    Li, Zhenyu
    Zeng, Lingyu
    Wu, Qingyun
    Qiao, Jianlin
    Chen, Chong
    Zheng, Junnian
    Cao, Jiang
    Xu, Kailin
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
    Mehta, Palak H.
    Fiorenza, Salvatore
    Koldej, Rachel M.
    Jaworowski, Anthony
    Ritchie, David S.
    Quinn, Kylie M.
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it
    Yin, Xuechen
    He, Lingfeng
    Guo, Zhigang
    [J]. IMMUNOLOGY, 2023, 169 (04) : 400 - 411
  • [9] Challenges of Anti-Mesothelin CAR-T-Cell Therapy
    Zhai, Xuejia
    Mao, Ling
    Wu, Min
    Liu, Jie
    Yu, Shicang
    [J]. CANCERS, 2023, 15 (05)
  • [10] One Year Kymriah® CAR-T-Cell Therapy in Germany
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 619 - 619